GILZ Analog Peptides for Selective p65 Sequestration in Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Alzheimer's and spinal cord injuries are limited in effectively addressing inflammation and neurodegeneration, with existing therapies often causing side effects and not adequately targeting the underlying inflammatory pathways.
Innovation Solution
Development of rationally designed peptide analogs that selectively sequester activated p65, a key regulator of inflammation, to inhibit NF-κβ transactivation, thereby reducing inflammation and neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat neurodegenerative diseases, then treatment coverage is provided, but side effects occur and inflammatory pathways are not adequately targeted
Solution Approach 1:
The patent uses peptide analogs as intermediary molecules that specifically bind to activated p65, preventing its interaction with DNA and co-activators. This mediator approach allows selective inhibition of the inflammatory pathway without the broad-spectrum effects and side effects associated with conventional anti-inflammatory therapies.
Solution Approach 2:
The invention modifies the natural p65 protein's function by changing the binding parameters through specifically designed peptide sequences. These peptide analogs alter the interaction parameters between p65 and its binding partners, enabling selective inhibition of pathological inflammatory responses while preserving normal physiological functions.
2Reliability
If existing therapies are used to treat neurodegenerative diseases, then treatment coverage is provided, but inflammatory pathways are not adequately targeted
Solution Approach 1:
The patent extracts and isolates the specific inflammatory pathway involving activated p65 from the complex network of cellular signaling pathways. By designing peptide analogs that specifically target this extracted pathway component, the therapy achieves precise inflammatory pathway targeting without requiring complex multi-target interventions.
Solution Approach 2:
The invention segments the NF-κB signaling pathway into specific targetable components, focusing on the activated p65 subunit. This segmentation allows for selective intervention at the p65 activation stage, simplifying the therapeutic approach compared to attempting to modulate the entire complex signaling cascade.
3Reliability
If Aβ accumulates in the CNS, then neurodegeneration progresses, but selective inhibition of p65 could ameliorate pathologies
Solution Approach 1:
The patent applies preliminary anti-action by preventing the formation of the harmful p65-DNA-coactivator complex before inflammatory gene transcription can occur. The peptide analogs bind to activated p65 in advance, blocking its ability to initiate the cascade of neuroinflammatory and pro-apoptotic gene expressions that lead to tissue damage.
Solution Approach 2:
The invention converts the harmful effect of Aβ-induced p65 activation into a beneficial therapeutic opportunity. By targeting the activated p65 that is normally responsible for inflammatory responses, the peptide analogs selectively inhibit the harmful pathway while potentially preserving or even enhancing protective inflammatory mechanisms through careful molecular design.
Data Source
AI summary
The present disclosure provides pharmaceutical compositions comprising rationally designed peptide analogs of the p65-TAD binding region of GILZ to selectively sequester activated p65. Structural and functional analyses suggest that select GILZ analog (GA) bind p65-TAD with optimum affinity, exhibit an estimated half minimal lethal dose comparable to known peptide drugs and suppress Aβ1-42 induced cytotoxicity. Furthermore, the present disclosure provides uses and methods of using the pharmaceutical compositions, and uses and methods of using pharmaceutical formulations comprising the pharmaceutical compositions, for the treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).